These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 15510610)

  • 21. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
    Xin Y; Han B; Lou J; Wu J; Niu Y
    Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y; Tokue A
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
    Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum carboxy-terminal cross-linked telopeptide of type I collagen reflects bone metastasis in hepatocellular carcinoma.
    Ueno T; Hashimoto O; Sugawara H; Ogata R; Kusaba N; Torimura T; Sata M; Tanikawa K
    Int J Oncol; 1998 Aug; 13(2):297-303. PubMed ID: 9664125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer.
    Aruga A; Koizumi M; Hotta R; Takahashi S; Ogata E
    Br J Cancer; 1997; 76(6):760-4. PubMed ID: 9310242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M; Jensen LT; Iversen P
    Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
    Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
    J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
    Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
    J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.
    Zhao H; Han KL; Wang ZY; Chen Y; Li HT; Zeng JL; Shen Z; Yao Y
    Med Sci Monit; 2011 Nov; 17(11):CR626-633. PubMed ID: 22037741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.
    Koizumi M; Yonese J; Fukui I; Ogata E
    BJU Int; 2001 Mar; 87(4):348-51. PubMed ID: 11251528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.